Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016

Details for Mechanism ID: 9974
Country/Region: Vietnam
Year: 2014
Main Partner: Ho Chi Minh City Provincial AIDS Committee
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $2,738,000 Additional Pipeline Funding: $762,000

NOTE: The following is taken from summaries released by PEPFAR on the PEPFAR Data Dashboard. They are incomplete summary paragraphs only and do not contain the full mechanism details. When the full narratives are released, we will update the mechanism pages accordingly.

Ho Chi Minh City (HCMC) Provincial AIDS Committee’s (PAC) goal is to provide a response to the HIV epidemic in HCMC and surrounding southern provinces. Target populations are high risk populations such as HIV-positive individuals, IDUs, female and male sex workers, and MSM. Objectives are:

1) Strengthen HCMC health system infrastructure to provide HIV prevention, care, and treatment services.

2) Support HIV/AIDS program’s integration into the government of Vietnam (GVN).

3) Promote HIV program sustainability by transitioning PEPFAR Vietnam financial support to the HCMC Department of Health (DOH) and/or Ministry of Health (MOH) for HIV service delivery staffing, equipment, and routine operating costs.

4) Monitor coverage and service delivery of HIV prevention, care, and treatment programs.

5) Support HIV/AIDS commodities, mainly OI drugs, HIV test kits, CD4 reagents and other diagnostic tests while working to identify a suitable transition mechanism.

6) Develop/evaluate cost-effective models of service delivery.

The HCMC PAC has developed a logic model to guide program transition planning. The HCMC People’s Committee has approved $500,000 of GVN funding for procurement of OI medications and methadone in 2014 and will use the National Health Insurance system to finance HIV drugs when available. PAC is working with stakeholders to develop program transition indicators to measure cost-efficient service delivery models, staffing and financial transition, as well as to maintain clinical service quality.

Pipeline was considered when setting the COP 14 budget request. A nine-month no-cost extension will be issued with pipeline to be used as funding. COP 14 funding will be used when the new grant year begins in 2015. This amount is at the current expenditure level.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $557,080
Care: TB/HIV (HVTB) $100,174
Care: Pediatric Care and Support (PDCS) $17,599
Laboratory Infrastructure (HLAB) $143,378
Strategic Information (HVSI) $111,226
Testing: HIV Testing and Counseling (HVCT) $237,994
Sexual Prevention: Other Sexual Prevention (HVOP) $93,687
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $93,481
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $154,631
Treatment: Adult Treatment (HTXS) $1,151,756
Treatment: Pediatric Treatment (PDTX) $76,994
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 68,440
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 200
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 380
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 85,920
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 8,360
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 15,080
HTS_TST Aggregated Age/sex: <15 Female 2015 200
HTS_TST Aggregated Age/sex: <15 Male 2015 380
HTS_TST Aggregated Age/sex: 15+ Female 2015 85,920
HTS_TST Aggregated Age/sex: 15+ Male 2015 15,080
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 76,800
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 101,580
HTS_TST Sum of Aggregated Age/Sex <15 2015 68,440
HTS_TST Sum of Aggregated Age/Sex <15 2015 580
HTS_TST Sum of Aggregated Age/Sex <15 2015 580
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 8,360
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 101,000
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 101,000
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 76,800
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 101,580
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 101,580
KP_MAT Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months 2015 1,460
KP_MAT Sex: Female 2015 210
KP_MAT Sex: Male 2015 1,250
KP_MAT Sum of Sex disaggregates 2015 1,460
KP_PREV By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2015 4,630
KP_PREV By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2015 418
KP_PREV By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2015 5,400
KP_PREV By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2015 4,000
KP_PREV By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2015 6,000
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2015 4,000
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2015 16,448
LAB_CAP By clinical laboratories 2015 21
LAB_CAP By site support type: Direct Service Delivery (DSD) 2015 21
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2015 21
LAB_CAP Sum of Site Support Type disaggregates 2015 21
PMTCT_ARV Life-long ART (including Option B+) 2015 610
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 640
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 610
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 160
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 450
PMTCT_ARV Sum of New and Current disaggregates 2015 610
PMTCT_ARV Sum of Regimen Type disaggregates 2015 610
PMTCT_ARV_NGI Life-long ART (including Option B+) 2015 610
PMTCT_ARV_NGI Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 640
PMTCT_ARV_NGI Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 610
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 160
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 450
PMTCT_ARV_NGI Sum of New and Current disaggregates 2015 610
PMTCT_ARV_NGI Sum of Regimen disaggregates 2015 610
PMTCT_EID By infants who received a virologic test within 2 months of birth 2015 540
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2015 40
PMTCT_EID By infants with a positive virologic test result within 12 months of birth 2015 10
PMTCT_EID Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) 2015 640
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2015 580
PMTCT_EID Sum of Infant Age disaggregates 2015 580
PMTCT_SITE By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women 2015 16
PMTCT_SITE By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services) 2015 17
PMTCT_SITE Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women 2015 16
PMTCT_SITE Sum of Numerator Support Type disaggregates 2015 16
PMTCT_SITE Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services) 2015 17
PMTCT_SITE_den Sum of Denominator Support Type disaggregates 2015 17
PMTCT_STAT By: Known positives at entry 2015 480
PMTCT_STAT By: Number of new positives identified 2015 160
PMTCT_STAT Number of new ANC and L&D clients 2015 71,000
PMTCT_STAT Number of new ANC and L&D clients 2015 82,000
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 65,000
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 80,000
PMTCT_STAT Sum of Positives Status disaggregates 2015 640
PMTCT_STAT_NGI By: Known positives at entry 2015 480
PMTCT_STAT_NGI By: Number of new positives identified 2015 160
PMTCT_STAT_NGI Number of new ANC and L&D clients 2015 82,000
PMTCT_STAT_NGI Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 80,000
PMTCT_STAT_NGI Sum of Positives Status disaggregates 2015 640
SITE_SUPP By program area/support type: Care and Support Direct Service Delivery (DSD) 2015 12
SITE_SUPP By program area/support type: HTC Direct Service Delivery (DSD) 2015 5
SITE_SUPP By program area/support type: HTC Technical Assistance-only (TA) 2015 9
SITE_SUPP By program area/support type: Key Populations Prevention Direct Service Delivery (DSD) 2015 11
SITE_SUPP By program area/support type: Key Populations Prevention Technical Assistance-only (TA) 2015 2
SITE_SUPP By program area/support type: Lab Direct Service Delivery (DSD) 2015 21
SITE_SUPP By program area/support type: PMTCT Direct Service Delivery (DSD) 2015 18
SITE_SUPP By program area/support type: PMTCT Technical Assistance-only (TA) 2015 38
SITE_SUPP By program area/support type: TB/HIV Direct Service Delivery (DSD) 2015 25
SITE_SUPP By program area/support type: Treatment Direct Service Delivery (DSD) 2015 12
SITE_SUPP Number of unique sites supported by PEPFAR 2015 153
TX_CURR Aggregated Age/Sex: <1 Female 2015 2
TX_CURR Aggregated Age/Sex: <1 Female 2015 7
TX_CURR Aggregated Age/Sex: <1 Male 2015 3
TX_CURR Aggregated Age/Sex: <1 Male 2015 8
TX_CURR Aggregated Age/Sex: <15 Female 2015 60
TX_CURR Aggregated Age/Sex: <15 Female 2015 585
TX_CURR Aggregated Age/Sex: <15 Male 2015 80
TX_CURR Aggregated Age/Sex: <15 Male 2015 630
TX_CURR Aggregated Age/Sex: 15+ Female 2015 4,285
TX_CURR Aggregated Age/Sex: 15+ Male 2015 8,121
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2015 13,621
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2015 140
TX_CURR Sum of Aggregated Age/Sex <15 2015 140
TX_CURR Sum of Aggregated Age/Sex <15 2015 1,215
TX_CURR Sum of Aggregated Age/Sex 15+ 2015 12,406
TX_CURR Sum of Aggregated Age/Sex disaggregates 2015 140
TX_CURR Sum of Aggregated Age/Sex disaggregates 2015 13,621
TX_CURR_NGI Aggregated Age/Sex: <1 Female 2015 7
TX_CURR_NGI Aggregated Age/Sex: <1 Male 2015 8
TX_CURR_NGI Aggregated Age/Sex: <15 Female 2015 585
TX_CURR_NGI Aggregated Age/Sex: <15 Male 2015 630
TX_CURR_NGI Aggregated Age/Sex: 15+ Female 2015 4,285
TX_CURR_NGI Aggregated Age/Sex: 15+ Male 2015 8,121
TX_CURR_NGI Number of adults and children receiving antiretroviral therapy (ART) 2015 13,621
TX_CURR_NGI Sum of Aggregated Age/Sex <15 2015 1,215
TX_CURR_NGI Sum of Aggregated Age/Sex 15+ 2015 12,406
TX_CURR_NGI Sum of Aggregated Age/Sex disaggregates 2015 13,621
TX_NEW Aggregated Grouping by Age: <1 Male 2015 8
TX_NEW Aggregated Grouping by Age/Sex: <1 Female 2015 7
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2015 50
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2015 60
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2015 678
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2015 1,137
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2015 1,925
TX_NEW Pregnancy status 2015 200
TX_NEW Sum of Aggregated Age/Sex disaggregates 2015 1,925
TX_RET Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 139
TX_RET Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 1,554
TX_RET Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 160
TX_RET_den Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 153
TX_RET_den Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 1,850
TX_RET_den Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 200
Cross Cutting Budget Categories and Known Amounts Total: $1,090,000
Human Resources for Health $750,000
Key Populations: Sex Workers $100,000
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Training of health workers and community outreach workers
Collection and use of strategic information on SWs and clients
Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Monitoring and evaluation of SW programs
Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Key Populations: MSM and TG $80,000
Training of health workers and community outreach workers
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Collection and use of strategic information
Monitoring and evaluation of MSM/TG programs
Education $75,000
Condoms: Commodities $85,000
Key Issues Identified in Mechanism
Tuberculosis